GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Forward PE Ratio

Molecular Partners AG (XSWX:MOLN) Forward PE Ratio : 0.00 (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Forward PE Ratio?

Molecular Partners AG's Forward PE Ratio for today is 0.00.

Molecular Partners AG's PE Ratio without NRI for today is 0.00.

Molecular Partners AG's PE Ratio for today is 0.00.


Molecular Partners AG Forward PE Ratio Historical Data

The historical data trend for Molecular Partners AG's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Forward PE Ratio Chart

Molecular Partners AG Annual Data
Trend 2019-12 2020-08 2021-02 2022-08
Forward PE Ratio
7.43 12.95 175.44 1.70

Molecular Partners AG Quarterly Data
2019-09 2019-12 2020-03 2020-06 2022-03
Forward PE Ratio 6.99 7.43 4.52 8.85 1.74

Competitive Comparison of Molecular Partners AG's Forward PE Ratio

For the Biotechnology subindustry, Molecular Partners AG's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Forward PE Ratio falls into.



Molecular Partners AG Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Molecular Partners AG  (XSWX:MOLN) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Molecular Partners AG Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.